李荣翠, 刘率男, 申竹芳. 果糖-1,6-二磷酸酶及其抑制剂的研究进展J. 药学学报, 2018,53(9): 1477-1483. doi: 10.16438/j.0513-4870.2018-0282
引用本文: 李荣翠, 刘率男, 申竹芳. 果糖-1,6-二磷酸酶及其抑制剂的研究进展J. 药学学报, 2018,53(9): 1477-1483. doi: 10.16438/j.0513-4870.2018-0282
LI Rong-cui, LIU Shuai-nan, SHEN Zhu-fang. Advances in the pharmacological function of FBPase and development of FBPase inhibitorsJ. Acta Pharmaceutica Sinica, 2018,53(9): 1477-1483. doi: 10.16438/j.0513-4870.2018-0282
Citation: LI Rong-cui, LIU Shuai-nan, SHEN Zhu-fang. Advances in the pharmacological function of FBPase and development of FBPase inhibitorsJ. Acta Pharmaceutica Sinica, 2018,53(9): 1477-1483. doi: 10.16438/j.0513-4870.2018-0282

果糖-1,6-二磷酸酶及其抑制剂的研究进展

Advances in the pharmacological function of FBPase and development of FBPase inhibitors

  • 摘要: 果糖-1,6-二磷酸酶(fructose 1,6-bisphosptase,FBPase)是位于糖异生过程中第二步的限速酶,在机体血糖调控中发挥重要的生理作用。因此,针对该酶的抑制剂将具有抗糖尿病活性。目前,已有数个FBPase抑制剂分别进入不同临床研究阶段,提示针对该靶点的抗糖尿病药物研发前景十分可观。除此以外,近年研究发现,FBPase还可参与和调节其他疾病如肿瘤的发生、发展过程等。本文将围绕FBPase的结构特征、生理作用、其与2型糖尿病糖异生和胰岛素分泌的关系、FBPase抑制剂的研究进展以及该酶在其他疾病中调控作用等方面作一综述。

     

    Abstract: Fructose 1, 6-bisphosptase (FBPase), a second rate-limiting enzyme in gluconeogenesis, has an important role in the control of gluconeogenesis, which involves in energy metabolism and glucose homeostasis. Inhibitors of FBPase exhibit an anti-diabetic activity. Some of FBPase inhibitors have entered the stage of clinical trials, which indicates that FBPase is a promising therapeutic target for the discovery and development of hypoglycemic drugs. In addition, recent studies have shown that FBPase can be used to treat other diseases such as the initiation and development of tumors in several cancer types. Here, we provide a review of the biological characteristics of FBPase and contributions of FBPase on gluconeogenesis and insulin secretion, the research and development of FBPase inhibitors and the regulatory role of FBPase in other diseases.

     

/

返回文章
返回